We are in the business of improving and saving lives. Every financial decision we make is measured against the positive human impact it will generate.
We use innovative finance to make medical products more affordable and accessible in under-served markets.
Our work helps life-science companies mitigate the business risks of bringing affordable medicines to people in need.
by Michael Anderson, Chief Executive Officer When future generations chart the COVID-19 pandemic, they will note that ‘business as usual’ was set aside to protect lives. Unprecedented collaboration between science, industry and government is driving new vaccine development at record speed. Chinese scientists shared the virus genome within days. Anti-viral treatments are being tested in…
by Michelle Akande, Vice President, Health Markets Significant progress has been made against infectious diseases over the past two decades. In 2004, an estimated 1.7 million people died of AIDS-related illness but by 2018, that figured had dropped to 770,000. Equally impressive strides have been made in the fight against malaria, with deaths decreasing by…
February 24, 2020 – MedAccess is pleased to announce the appointment of Hema Srinivasan as the social finance company’s new Chief Access Officer. Hema brings over a decade of experience in healthcare, market shaping and access programmes to reach people with life-saving medicines, medical devices and diagnostics. Hema will join MedAccess at the end of…
The price of new BASF Interceptor® G2 bednets will be reduced by 40%, thanks to a new MedAccess partnership. 8 October 2019 – Today in Lyon, MedAccess announced a four-year agreement with global chemical producer BASF to reduce the price of 35 million next generation bednets, the BASF Interceptor® G2. The collaboration between MedAccess, BASF…
